StockSignal
  • Screen for fundamentally interesting stocks
Sign in
MicroPort Scientific Corporation logo

MicroPort Scientific Corporation

0853 · XHKG · Medical Devices · China

Debt To Equity Ratio
Market Capitalization20.70B HKD
Trailing P/E-85.87 HKD
52-Week Change6.48 HKD
Beta0.3920 HKD

MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, Europe, Middle East and Africa, Japan, and internationally. The company's Cardiovascular Devices segment offers medical solutions for the treatment of coronary artery-related diseases; and coronary stents, related delivery systems, balloon catheters, accessories, and active devices. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma products, and other professional implants and instruments. The company's Cardiac Rhythm Management Business segment offers defibrillators, cardiac resynchronization therapy devices, and pacemakers. Its Endovascular and Peripheral Vascular Devices segment provides disease solutions for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection aneurysms, and other arteriovenous related diseases. The company's Neurovascular Devices segment offers neurovascular therapeutic and access devices for cerebrovascular diseases. The company's Surgical Robot Business segment offers surgical robots comprising robot ontology, control algorithm, electrical engineering, image-based navigation, and precision imaging. Its Surgical Devices segment provides surgical devices. It is also involved in the distribution of medical devices. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.

Industry

Medical Devices

Healthcare sector · China

Stories

Structural patterns identified in MicroPort Scientific Corporation

No stories identified yet.

Key Metrics

Market Capitalization
20.70BHKD
NormalMar 18, 2026
Trailing P/E
-85.87HKD
ExtremeMar 18, 2026
Revenue (TTM)
7.99BHKD
NormalMar 18, 2026
Profit Margin
-16.06%
NormalMar 18, 2026
Beta
0.3920HKD
NormalMar 18, 2026
52-Week Change
6.48HKD
ExtremeMar 18, 2026

This company does not currently pay dividends.

Valuation8
Market Capitalization
20.70BHKD
NormalMar 18, 2026
Enterprise Value
156.10BHKD
NormalMar 18, 2026
Trailing P/E
-85.87HKD
ExtremeMar 18, 2026
Forward P/E
71.11HKD
AboveNormalMar 18, 2026
Price to Sales (TTM)
18.18HKD
NormalMar 18, 2026
Price to Book (MRQ)
3.80HKD
NormalMar 18, 2026
Enterprise to Revenue
19.55HKD
NormalMar 18, 2026
Enterprise to EBITDA
687.79HKD
ExtremeMar 18, 2026
Profitability & Growth57
Profit Margin
-16.06%
NormalMar 18, 2026
Operating Margin
0.22%
NormalMar 18, 2026
Return on Assets (TTM)
-0.0113HKD
NormalMar 18, 2026
Return on Equity (TTM)
-0.1605HKD
NormalMar 18, 2026
Revenue (TTM)
7.99BHKD
NormalMar 18, 2026
Revenue per Share (TTM)
0.5540HKD
NormalMar 18, 2026
Quarterly Revenue Growth
-0.0200HKD
NormalMar 18, 2026
Gross Profit (TTM)
4.32BHKD
NormalMar 18, 2026
EBITDA
226.96MHKD
ExtremeMar 18, 2026
Net Income (TTM)
-1.28BHKD
NormalMar 18, 2026
Operating Cash Flow (TTM)
-217.43MHKD
NormalMar 18, 2026
Levered Free Cash Flow (TTM)
1.60BHKD
NormalMar 18, 2026
Trailing Annual Dividend Rate
0.00HKD
NormalMar 18, 2026
Trailing Annual Dividend Yield
0.00%
NormalMar 18, 2026
5-Year Average Dividend Yield
23.00%
ExtremeMar 18, 2026
Payout Ratio
0.00HKD
NormalMar 18, 2026
Minority Interest (Equity)
541.37M
NormalFY2024 · Dec 31, 2024
Revenue
1.03B
NormalFY2024 · Dec 31, 2024
Cost of Goods Sold
456.97M
NormalFY2024 · Dec 31, 2024
Gross Profit
574.09M
NormalFY2024 · Dec 31, 2024
Operating Income
-117.53M
NormalFY2024 · Dec 31, 2024
Pre-tax Income
-224.78M
NormalFY2024 · Dec 31, 2024
Income Tax Expense
43.67M
NormalFY2024 · Dec 31, 2024
Net Income
-268.46M
NormalFY2024 · Dec 31, 2024
EBIT
-122.55M
NormalFY2024 · Dec 31, 2024
ebitda-income
-6.76M
NormalFY2024 · Dec 31, 2024
Research & Development
216.51M
NormalFY2024 · Dec 31, 2024
Selling, General & Administrative
484.68M
NormalFY2024 · Dec 31, 2024
Other Operating Expenses
11.63M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Income
22.75M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Expense
102.24M
NormalFY2024 · Dec 31, 2024
EPS (Basic)
-0.1168
NormalFY2024 · Dec 31, 2024
EPS (Diluted)
-0.1215
NormalFY2024 · Dec 31, 2024
Basic Shares Outstanding
1.83BShares
NormalFY2024 · Dec 31, 2024
Diluted Shares Outstanding
1.83BShares
NormalFY2024 · Dec 31, 2024
Net Income from Continuing Operations
-224.78M
NormalFY2024 · Dec 31, 2024
Minority Interests (P&L)
54.42M
NormalFY2024 · Dec 31, 2024
Preferred Stock Dividends
0.00
NormalFY2024 · Dec 31, 2024
Operating Cash Flow
-139.99M
NormalFY2024 · Dec 31, 2024
Free Cash Flow
-158.10M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents (End of Period)
713.00M
NormalFY2024 · Dec 31, 2024
Net Income (CF Statement)
-224.78M
NormalFY2024 · Dec 31, 2024
Stock-based Compensation
27.77M
NormalFY2024 · Dec 31, 2024
Other Non-cash Items
92.86M
NormalFY2024 · Dec 31, 2024
Change in Accounts Receivable (CF)
-83.41M
NormalFY2024 · Dec 31, 2024
Change in Other Assets/Liabilities
47.58M
NormalFY2024 · Dec 31, 2024
Capital Expenditures
-77.68M
NormalFY2024 · Dec 31, 2024
Net Intangibles (CF)
-20.15M
NormalFY2024 · Dec 31, 2024
Net Acquisitions
-50.62M
NormalFY2024 · Dec 31, 2024
Purchase of Investments
-723.70M
NormalFY2024 · Dec 31, 2024
Sale of Investments
716.97M
NormalFY2024 · Dec 31, 2024
Other Investing Activity
144.00K
NormalFY2024 · Dec 31, 2024
Net Investing Cash Flow
-134.88M
NormalFY2024 · Dec 31, 2024
Long-term Debt Issuance
900.53M
NormalFY2024 · Dec 31, 2024
Long-term Debt Payments
-838.05M
NormalFY2024 · Dec 31, 2024
Other Financing Charges
26.31M
NormalFY2024 · Dec 31, 2024
Net Financing Cash Flow
54.37M
NormalFY2024 · Dec 31, 2024
Financial Strength26
Shares Outstanding
1.85BShares
NormalMar 18, 2026
Float Shares
963.85MHKD
NormalMar 18, 2026
% Held by Insiders
0.4398HKD
NormalMar 18, 2026
% Held by Institutions
0.0800HKD
NormalMar 18, 2026
Total Cash (MRQ)
7.50BHKD
NormalMar 18, 2026
Total Cash per Share (MRQ)
0.5180HKD
NormalMar 18, 2026
Total Debt (MRQ)
13.77BHKD
NormalMar 18, 2026
Total Debt to Equity (MRQ)
148.81HKD
ExtremeMar 18, 2026
Current Ratio (MRQ)
1.42HKD
NormalMar 18, 2026
Book Value per Share (MRQ)
2.64HKD
NormalMar 18, 2026
Total Assets
3.63B
NormalFY2024 · Dec 31, 2024
Total Current Assets
1.74B
NormalFY2024 · Dec 31, 2024
Total Liabilities
2.49B
NormalFY2024 · Dec 31, 2024
Total Non-current Assets
1.90B
NormalFY2024 · Dec 31, 2024
Total Non-current Liabilities
1.31B
NormalFY2024 · Dec 31, 2024
Total Current Liabilities
1.18B
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents
713.00M
NormalFY2024 · Dec 31, 2024
Other Short-term Investments
261.49M
NormalFY2024 · Dec 31, 2024
Accounts Receivable
265.64M
NormalFY2024 · Dec 31, 2024
Inventory
379.29M
NormalFY2024 · Dec 31, 2024
Accounts Payable
174.58M
NormalFY2024 · Dec 31, 2024
Short-term Debt
505.34M
NormalFY2024 · Dec 31, 2024
Long-term Debt
1.18B
NormalFY2024 · Dec 31, 2024
Common Stock (Book)
18.00K
NormalFY2024 · Dec 31, 2024
Retained Earnings
-1.60B
NormalFY2024 · Dec 31, 2024
Total Shareholders' Equity
1.14B
NormalFY2024 · Dec 31, 2024
Market & Technical9
52-Week Low
6.10HKD
NormalMar 18, 2026
52-Week High
16.28HKD
NormalMar 18, 2026
52-Week Change
6.48HKD
ExtremeMar 18, 2026
Beta
0.3920HKD
NormalMar 18, 2026
50-Day MA
11.26HKD
NormalMar 18, 2026
200-Day MA
11.40HKD
NormalMar 18, 2026
Avg 10-Day Volume
12.11MHKD
NormalMar 18, 2026
Avg 30-Day Volume
11.34MHKD
NormalMar 18, 2026
Diluted EPS (TTM)
-0.7300HKD
NormalMar 18, 2026

Coordination

Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination

Supply Chain

Medical Devices Supply Chain

The medical devices supply chain is shaped by three structural constraints that most manufacturing industries do not face: a regulatory classification cascade where risk level determines the years of validation required before a product can be sold, sterilization and biocompatibility requirements that restrict which materials and processes are permitted, and installed base dependency where hospitals commit to ecosystems that cannot be switched without replacing training, consumables, and data infrastructure.

StockSignal
  • Blog
  • Industries
  • Glossary
  • Stories
  • Coordinations
  • Constraint Archetypes
  • Legal

Contact

© 2026 StockSignal. All rights reserved.